M

MDxHealth SA
NASDAQ:MDXH

Watchlist Manager
MDxHealth SA
NASDAQ:MDXH
Watchlist
Price: 1.94 USD 3.74% Market Closed
Market Cap: 96m USD
Have any thoughts about
MDxHealth SA?
Write Note

Net Margin
MDxHealth SA

-49.5%
Current
-97%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-49.5%
=
Net Income
-59.4m
/
Revenue
119.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
BE
MDxHealth SA
NASDAQ:MDXH
96m USD
-50%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
150.5B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-14%
Country BE
Market Cap 96m USD
Net Margin
-50%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 320.1B USD
Net Margin
9%
Country US
Market Cap 150.5B USD
Net Margin
13%
Country US
Market Cap 120.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.9B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.5B EUR
Net Margin
-14%
No Stocks Found

MDxHealth SA
Glance View

Market Cap
96m USD
Industry
Biotechnology

MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

MDXH Intrinsic Value
9.14 USD
Undervaluation 79%
Intrinsic Value
Price
M

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-49.5%
=
Net Income
-59.4m
/
Revenue
119.9m
What is the Net Margin of MDxHealth SA?

Based on MDxHealth SA's most recent financial statements, the company has Net Margin of -49.5%.